| Alterations of platelet function and clot formation kinetics after in vitro exposure to anti-A and -B. | |
| | |
MedLine Citation:
|
PMID: 22624532 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: ABO-mismatched platelets (PLTs) are commonly transfused despite reported complications. We hypothesized that because PLTs possess A and B antigens on their surface, ABO-mismatched transfused or recipient PLTs could become activated and/or dysfunctional after exposure to anti-A or -B in the transfused or recipient plasma. We present here in vitro modeling data on the functional effects of exposure of PLTs to ABO antibodies. STUDY DESIGN AND METHODS: PLT functions of normal PLTs of all ABO types were assessed before and after incubation with normal saline, ABO-identical plasma samples, or O plasma samples with varying titers of anti-A and anti-B (anti-A/B). Assays used for this assessment include PLT aggregation, clot kinetics, thrombin generation, PLT cytoskeletal function, and mediator release. RESULTS: Exposure of antigen-bearing PLTs to O plasma with moderate to high titers of anti-A/B significantly inhibits aggregation, prolongs PFA-100 epinephrine closure time, disrupts clot formation kinetics, accelerates thrombin generation, reduces total thrombin production, alters PLT cytoskeletal function, and influences proinflammatory and prothrombotic mediator release. CONCLUSIONS: Our findings demonstrate a wide range of effects that anti-A/B have on PLT function, clot formation, thrombin generation, PLT cytoskeletal function, and mediator release. These data provide potential explanations for clinical observations of increased red blood cell utilization in trauma and surgical patients receiving ABO-nonidentical blood products. Impaired hemostasis caused by anti-A/B interacting with A and B antigens on PLTs, soluble proteins, and perhaps even endothelial cells is a potential contributing factor to hemorrhage in patients receiving larger volumes of ABO-nonidentical transfusions. |
| | |
Authors:
|
Majed A Refaai; Jessie Carter; Kelly F Henrichs; Donna C Davidson; Stephen J Pollock; Ann E Casey; Sherry L Spinelli; Richard P Phipps; Charles W Francis; Neil Blumberg |
Publication Detail:
|
Type: Evaluation Studies; In Vitro; Journal Article; Research Support, N.I.H., Extramural Date: 2012-05-25 |
Journal Detail:
|
Title: Transfusion Volume: 53 ISSN: 1537-2995 ISO Abbreviation: Transfusion Publication Date: 2013 Feb |
Date Detail:
|
Created Date: 2013-02-06 Completed Date: 2013-03-28 Revised Date: 2013-04-16 |
Medline Journal Info:
|
Nlm Unique ID: 0417360 Medline TA: Transfusion Country: United States |
Other Details:
|
Languages: eng Pagination: 382-93 Citation Subset: IM |
Copyright Information:
|
© 2012 American Association of Blood Banks. |
Affiliation:
|
Department of Pathology and Laboratory Medicine, the James P. Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA. majed_refaai@urmc.rochester.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
ABO Blood-Group System
/
immunology* Adult Antibodies / pharmacology* Blood Coagulation / drug effects*, physiology Blood Grouping and Crossmatching Blood Platelets / drug effects*, immunology, physiology* Female Humans Kinetics Male Middle Aged Platelet Aggregation / drug effects, physiology Time Factors Titrimetry |
| Grant Support | |
ID/Acronym/Agency:
|
ES01247/ES/NIEHS NIH HHS; HL095467/HL/NHLBI NIH HHS; HL100051/HL/NHLBI NIH HHS; P30 ES001247/ES/NIEHS NIH HHS; R01 HL095467/HL/NHLBI NIH HHS; RC1 HL100051/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/ABO Blood-Group System; 0/Antibodies |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 versus 0.9% NaCl flui...
Next Document: Laxiflorolides A and B, Epimeric Bishomoditerpene Lactones from Isodon eriocalyx.